...mOS was 543 vs 550 days (p=073). mPFS was 326 vs 343 days (p=0.86). mOS of Stage IIIA was 489 vs 775 days (p=0.14), of s...
...mos (14.7- 18.1 mos). 1 yr survival 62%, 2 yr 36% and 3 yr 28%. Age >65, >75 and >80 were not adverse prognostic factors...
...mos (95% CI: 4.9-9.0), 12-month survival 34% (95% CI: 20-63%) and median survival 9.3 mos (95% CI: 5.9-11.4) were observ...
...mos, the median PFS was 9.8 mos after 1st line and 4.7 mos after 2nd line therapy. The median OS was 56 mos.,Treatment o...
...mos. The primary endpoint was the % change in BMD at the lumbar spine at 12 mos.,In the main trial, patients were matche...
...mos, ave. followup is 31 mos from RP. There have been no biochemical (PSA) relapses and 26/28 (93%) remain free of disea...
...mos; range 2-85 mos). Eighteen percent of the localized group subsequently developed metastatic RCC (mRCC) at a median o...
...mos, median 12 mos). 20/80 pts dropped out the study after 5- 24 mos: 2 pts due to PSADT, 2 to PSA > 10 ng/ml, 6 to upgr...
...mos for the HER2(3+) group and 15.7 mos for the HER2(0-2+) group. Median time to progression was 3 and 6 mos for the HER...
...mos. All 5 pts who had an increase in PSA specific T-cell response >6 fold remain alive 35-45+mos after enrollment compa...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
